Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2774445 | Endocrinología y Nutrición | 2007 | 7 Pages |
Abstract
Interferon-alpha is indicated in patientswith somatostatin analog resistance, especially in carcinoids. Chemotherapy should be considered in poorly differentiated tumors or in patients with progressive disease and no response to somatostatin analogs and/or interferon. The risk-benefit ratio of using aggressive therapy should always be considered in patients who, despite having disseminated disease, usually have prolonged survival.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Clinical Biochemistry
Authors
Mónica Marazuela AzpÃroz, E. Ignacio Bernabeu Morón,